Mergers and acquisitions
Overview Insights People
Subscribe to our insights

Publication

M&A Outlook 2024

With inflation easing and deal appetite rising, we expect to see promising early signs of a rebound in M&A activity.

January 31, 2024

Corporate, M&A and securities
Growth amidst drought

Publication

A study from Norton Rose Fulbright sees green shoots amid the challenges

The M&A Journal recently spoke with Global Head of Corporate, M&A and Securities Ayse Yüksel Mahfoud to discuss the Glob...

December 13, 2023

Mergers and acquisitions
Outlook 2021 C

Publication

M&A hub: Developments driving and shaping M&A

Key legal and regulatory developments driving and shaping M&A

December 01, 2023

Corporate, M&A and securities
American Flag

Publication

The election: How each candidate is likely to affect the future of M&A

Five Norton Rose Fulbright partners held a panel discussion on September 24 to address what dealmakers can expect from e...

October 22, 2024

Corporate, M&A and securities
FTC’s watchdog role in pharma mergers: Road bumps and the way forward

Publication

FTC’s watchdog role in pharma mergers: Road bumps and the way forward

The FTC's revised merger guidelines issued in 2023 signify a substantial alteration in antitrust enforcement, notably im...

October 18, 2024

Corporate, M&A and securities
MA

Publication

M&A Outlook 2024

With inflation easing and deal appetite rising, we expect to see promising early signs of a rebound in M&A activity.

January 31, 2024

Corporate, M&A and securities
Growth amidst drought

Publication

A study from Norton Rose Fulbright sees green shoots amid the challenges

The M&A Journal recently spoke with Global Head of Corporate, M&A and Securities Ayse Yüksel Mahfoud to discuss the Glob...

December 13, 2023

Mergers and acquisitions
Outlook 2021 C

Publication

M&A hub: Developments driving and shaping M&A

Key legal and regulatory developments driving and shaping M&A

December 01, 2023

Corporate, M&A and securities
American Flag

Publication

The election: How each candidate is likely to affect the future of M&A

Five Norton Rose Fulbright partners held a panel discussion on September 24 to address what dealmakers can expect from e...

October 22, 2024

Corporate, M&A and securities
FTC’s watchdog role in pharma mergers: Road bumps and the way forward

Publication

FTC’s watchdog role in pharma mergers: Road bumps and the way forward

The FTC's revised merger guidelines issued in 2023 signify a substantial alteration in antitrust enforcement, notably im...

October 18, 2024

Corporate, M&A and securities
More